Roche reports PML case in patient on Ocrevus

Roche (SIX:ROG; OTCQX:RHHBY) is investigating a case of progressive multifocal leukoencephalopathy (PML) in a multiple sclerosis patient following treatment with Ocrevus ocrelizumab, the company told BioCentury.

The pharma said the patient had been treated with Tysabri natalizumab for three years until February before switching to Ocrevus in April. The patient, who was John Cunningham virus (JCV)-positive, received one dose of Ocrevus as part of a German compassionate use program. Roche said that according to the treating physician, the case is a "carry-over" from Tysabri treatment...